Accès ouvert
2026
review
OpenAlex
Santenna Chenchula, Suresh Kumar Srinivasamurthy, Vinnyfred Vincent, Himani Thakkar et autres
Background: Childhood and adolescent acute lymphoblastic leukemia (ALL) survival outcomes have improved significantly, but treatment-related toxicities (TRTs) remain a major concern affecting dose intensity and quality of life. Germline pharmacogenetic variations contribute to inter-individual differences in chemotherapy response, yet consistent replication of …
in, ae, us, ch
(code pays fourni par la source)
Accès ouvert
2025
article
OpenAlex
Swetambri Sharma, Shuvadeep Ganguly, Kamali Murugadoss, Smita Kayal et autres
Background: Understanding interindividual variability in treatment response and toxicity is essential for optimizing outcomes in pediatric acute lymphoblastic leukemia (ALL). Molecular and pharmacogenetic markers hold promise in predicting treatment efficacy and adverse effects, particularly in genetically diverse populations. This protocol outlines the …
in, ch
(code pays fourni par la source)
Accès ouvert
2025
preprint
OpenAlex
Swetambri Sharma, Shuvadeep Ganguly, Kamali Murugadoss, Smita Kayal et autres
BACKGROUND Understanding inter-individual variability in treatment response and toxicity is essential for optimizing outcomes in pediatric acute lymphoblastic leukemia (ALL). Molecular and pharmacogenetic markers hold promise in predicting treatment efficacy and adverse effects, particularly in genetically diverse populations. This protocol outlines the …
Accès ouvert
2023
article
OpenAlex
Ramit Kundu, Kamali Murugadoss, Meerabai Manoharan, Jharna Mandal
BACKGROUND: Most studies on biocide resistance and its genetic determinants arise from environmental or food-borne microbial isolates and only a few from clinically relevant isolates. OBJECTIVES: This study determines the proportion of biocide resistance against five commonly used biocides and detects biocide …
in
(code pays fourni par la source)